What is pneumonia? Education and communication between physicians
Find out how well you know the answer to this interesting question and learn more about education and communication in medical care.
Fungal infections and waning treatments
What are the problems with evolving invasive fungal strains, and what is being done to combat them? Read our original article investigating the emerging burden of anti-fungal resistance.
Related news and insights
The board of directors of Shanghai Junishi Biosciences is pleased to announce that on 28 January 2023, pursuant to relevant regulations of the Drug Administration Law, the National Medical Products Administration (the NMPA) conducted urgent review and approval under Special Examination and Approval of Drugs and conditionally approved deuremidevir hydrobromide tablets (trade name: Mindewei, product code: VV116/JT001, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 Category 1 innovative drug for marketing, which was applied by Shanghai Vinnerna Biosciences Co., Ltd a subsidiary controlled by the Company, for the treatment of adult patients with mild to moderate coronavirus disease 2019
Novavax participated in the FDA Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) meeting, which resulted in a unanimous vote recommending harmonizing vaccine strain composition of primary series and booster doses. During the meeting, Novavax shared data demonstrating that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373), when used as a booster induces a broad functional immune response, including against forward drift variants.
The FDA has stated that AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorised for Emergency Use for pre-exposure prophylaxis (prevention) of COVID-19 in the US until further notice, due to the sustained high frequency of circulating SARS-CoV-2 variants that Evusheld does not retain in vitro neutralisation against
Respiratory Syncytial Virus is a virus that causes infections of the lungs and airways. It commonly appears during the coldest and wettest months of the year, similarly to the influenza virus. In adults and older children the symptoms are commonly mild, with cold-like symptoms such as rhinitis or coughing.
Related Clinical Trials
Your peers are looking at...
What are infectious diseases caused by?
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. They can be transmitted from person to person, by insects or other animals, or acquired by consuming contaminated food or water, or breathing in contaminated droplets in the air.
Common infectious diseases
Some of the more common infectious diseases include sexually transmitted diseases such as chlamydia, syphilis, HIV and herpes simplex 2; respiratory infections such as the common cold, influenza and COVID-19; and gastrointestinal infections including E.Coli, norovirus and salmonella.
Signs and symptoms of infectious diseases
Signs and symptoms for infectious diseases vary depending on the organism and site of infection but commonly include respiratory symptoms, gastrointestinal symptoms, fever, and fatigue. Severe infections may require hospitalisation and can be life-threatening.
Treatment of infectious diseases
Management strategies for infectious diseases vary depending on the infection. Some infections can be cleared completely with treatment, whilst some infections are managed in the long term without clearance. For instance, HIV can now be managed as a life-long chronic condition with an armamentarium of antiretroviral treatment (ART) combinations.
Preventing infectious diseases
Some infectious diseases can be prevented by vaccination. Indeed, immunisation programmes have greatly reduced the prevalence and burden of infectious diseases such as diphtheria, tetanus, pertussis, polio, influenza, and measles around the world. More targeted vaccination programmes include HPV vaccinations for cervical cancer in young women, and herpes zoster vaccination in the elderly.